Debra A Gervais1, Ronald S Arellano. 1. Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, White 270, 55 Fruit St, Boston, MA 02214, USA. dgervais@partners.org
Abstract
OBJECTIVE: This report reviews the current clinical status of percutaneous ablation of hepatocellular carcinoma (HCC). CONCLUSION: HCC is increasing in incidence. Multiple percutaneous ablation methods are now available for primary treatment or for bridging to transplantation. Percutaneous ethanol instillation and radiofrequency ablation are the most extensively evaluated percutaneous treatments for HCC. Newer technologies are being evaluated and may change future practice patterns.
OBJECTIVE: This report reviews the current clinical status of percutaneous ablation of hepatocellular carcinoma (HCC). CONCLUSION: HCC is increasing in incidence. Multiple percutaneous ablation methods are now available for primary treatment or for bridging to transplantation. Percutaneous ethanol instillation and radiofrequency ablation are the most extensively evaluated percutaneous treatments for HCC. Newer technologies are being evaluated and may change future practice patterns.
Authors: Adam N Wallace; Ross Vyhmeister; Andy C Hsi; Clifford G Robinson; Randy O Chang; Jack W Jennings Journal: Interv Neuroradiol Date: 2015-10-23 Impact factor: 1.610
Authors: Mishal Mendiratta-Lala; William R Masch; Kimberly Shampain; Andrew Zhang; Alexandria S Jo; Sarah Moorman; Anum Aslam; Katherine E Maturen; Matthew S Davenport Journal: Radiol Imaging Cancer Date: 2020-01-31